

Special Issue

Restoring Ethical and Effective Communication about Vaccination

Message from the Guest Editors

Vaccination, a topic that had long been neglected in the broader public interest, found itself in the midst of a vigorous and polarized debate during the COVID-19 pandemic. Much emphasis has been placed on particular positions and policies regarding vaccination. However, as both the masses and health professionals deal with fatigue, frustration, and challenges to their trust, it is time to reemphasize *how* we communicate, as much or more than *what* we communicate. Time is of the essence, as there is an urgent need for a range of new vaccinations—there are already warnings of a 'triple pandemic' of COVID-19, flu, and respiratory syncytial virus this year—which may become part of 21st century life and beyond. Similarly, we must restore focus and momentum on vaccine development against globally important diseases such as malaria and viral hemorrhagic fevers. In this Special Issue, we invite data, insights, exploration, and reflection from across biomedical, social science, and humanities disciplines on this ethical imperative—to restore trust and, with it, health.

Guest Editors

Prof. Dr. Arri Eisen

Department of Biology, Institute for the Liberal Arts, Emory University,
Atlanta, GA 30322, USA

Dr. Odaro John Huckstep

United States Air Force Academy, Colorado Springs, CO 80840, USA

Deadline for manuscript submissions

closed (1 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/147331

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).